Related Experiment Video
Updated: Aug 8, 2026
Evaluation of Polymeric Gene Delivery Nanoparticles by Nanoparticle Tracking Analysis and High-throughput Flow Cytometry
Published on: March 1, 2013
Nanoemulsions as Gene Delivery in Mucopolysaccharidosis Type I-A Mini-Review
Paweł Zapolnik1, Antoni Pyrkosz2
1College of Medical Sciences, University of Rzeszów, 35-959 Rzeszów, Poland.
Abstract:
Mucopolysaccharidosis type I (MPS I) is a rare monogenic disease in which glycosaminoglycans' abnormal metabolism leads to the storage of heparan sulfate and dermatan sulfate in various tissues. It causes its damage and impairment. Patients with the severe form of MPS I usually do not live up to the age of ten. Currently, the therapy is based on multidisciplinary care and enzyme replacement therapy or hematopoietic stem cell transplantation. Applying gene therapy might benefit the MPS I patients because it overcomes the typical limitations of standard treatments. Nanoparticles, including nanoemulsions, are used more and more in medicine to deliver a particular drug to the target cells. It allows for creating a specific, efficient therapy method in MPS I and other lysosomal storage disorders. This article briefly presents the basics of nanoemulsions and discusses the current state of knowledge about their usage in mucopolysaccharidosis type I.
Insights
Mucopolysaccharidosis type I (MPS I) is a rare genetic disorder. Nanoemulsions offer a promising gene therapy approach for MPS I, potentially overcoming limitations of current treatments for this lysosomal storage disorder.
Area of Science:
- Biochemistry
- Genetics
- Nanomedicine
Background:
- Mucopolysaccharidosis type I (MPS I) is a rare monogenic lysosomal storage disorder.
- Abnormal glycosaminoglycan metabolism leads to heparan and dermatan sulfate accumulation, causing multi-organ damage.
- Severe MPS I often results in mortality before age ten.
Purpose of the Study:
- To explore the potential of nanoemulsions as a drug delivery system for MPS I.
- To review the current applications of nanoemulsions in treating MPS I and similar disorders.
Main Methods:
- Review of existing literature on nanoemulsions and their application in lysosomal storage disorders.
- Analysis of nanoemulsion properties relevant to targeted drug delivery.
Main Results:
- Nanoemulsions demonstrate potential for targeted delivery of therapeutic agents.
- This approach may overcome limitations associated with conventional MPS I therapies.
- Gene therapy utilizing nanoemulsions could offer a specific and efficient treatment strategy.
Conclusions:
- Nanoemulsions represent a promising platform for developing advanced therapies for MPS I.
- Further research into nanoemulsion-based gene therapy is warranted for lysosomal storage disorders.
